(Q53348995)

English

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. (English)

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Colleoni M

1

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

Price K

2

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

Castiglione-Gertsch M

3

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

Goldhirsch A

4

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

Coates A

5

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

Lindtner J

6

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

Collins J

7

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

Gelber RD

8

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

Thürlimann B

9

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

Rudenstam CM

10

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

publication date

1 October 1998

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

European Journal of Cancer

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

34

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

1693-1700

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

11

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

Dose-response in the treatment of breast cancer: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-response is alive and well

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug dosage and remission duration in childhood lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose response evaluation of adriamycin in human neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical implications of tumor-cell heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-response effect of adjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen and combination chemotherapy as adjuvant treatment in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer: 8 year results

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The dose dilemma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900209-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(98)00209-3

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/9893654

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53348995&oldid=1966904143"